 |
市場調查報告書
商品編碼
1812416
他汀類藥物市場按產品類型、藥物類別、適應症、他汀類藥物類型、劑型、強度、銷售管道、年齡層、性別、分銷管道和地區分類Statins Market, By Product Type, By Drug Class, By Indication Prevention of Myocardial, By Type of Statin, By Formulation, By Strength, By Sales Channel, By Age Group, By Gender, By Distribution Channel, By Geography |
||||||
預計 2025 年他汀類藥物市場價值將達到 172.5 億美元，到 2032 年預計將達到 249.6 億美元，2025 年至 2032 年的複合年成長率為 5.42%。
| 報告範圍 | 報告詳細資訊 | ||
|---|---|---|---|
| 基準年 | 2024 | 2025年的市場規模 | 172.5億美元 |
| 效能數據 | 2020年至2024年 | 預測期 | 2020年至2024年 |
| 預測期：2025-2032年複合年成長率： | 5.42% | 2032年的價值預測 | 249.6億美元 |
全球他汀類藥物市場是心血管領域最重要的醫藥區隔之一，涵蓋了徹底改變全球心臟病治療和預防的降膽固醇藥物。他汀類藥物的科學名稱為HMG-CoA還原酶抑制劑，透過抑制肝臟中負責膽固醇合成的酵素發揮作用，有效降低低密度脂蛋白(LDL)膽固醇水平，並最大限度地降低心血管風險因素。受高膽固醇症盛行率上升、心血管疾病意識增強以及全球老齡人口成長等因素的影響，該市場正在經歷顯著成長。
市面上提供各式各樣的他汀類藥物，包括Atorvastatin、Simvastatin、rosuvastatin他汀、普伐他汀和洛伐他汀，並提供多種劑型和規格，以滿足不同患者的需求。心血管疾病仍是全球主要死因，他汀類藥物已成為第一級和第二級預防策略的基石，大量臨床證據證明其在減少重大不利事件的有效性。市場格局以品牌藥和非專利藥並存為特徵，專利到期對定價動態產生重大影響，同時也提高了全球不同經濟地區患者的用藥可及性。
市場動態
全球他汀類藥物市場受到多種強勁促進因素的支撐。心血管疾病和高膽固醇血症盛行率的上升，尤其是在已開發國家和開發中國家久坐不動的生活方式、不健康的飲食習慣和肥胖率持續上升的背景下，是關鍵的成長催化劑。老年人口的成長，本身就具有較高的高膽固醇症風險，這催生了對降膽固醇療法的持續需求，而醫療併發症的增加和保險覆蓋範圍的擴大也提高了市場可及性。預防保健意識的增強和定期膽固醇篩檢計畫的實施，使得人們能夠更早診斷和開始治療，從而進一步擴大了需要他汀類藥物治療的患者群體。
然而，市場面臨許多限制因素，包括主要品牌他汀類藥物專利到期後學名藥的廣泛供應，這導致價格競爭加劇，製藥公司的利潤率下降。對他汀類藥物相關副作用（例如肌肉相關症狀、肝酵素升高和潛在的糖尿病風險）的安全性擔憂，導致一些醫生和患者猶豫不決，從而影響了處方模式。此外，包括PCSK9抑制劑和新型調脂藥物在內的替代降膽固醇療法的出現，對傳統的他汀類藥物治療構成了競爭挑戰。監管的複雜性以及新劑型和新適應症的嚴格核准流程，為市場准入和創新設置了障礙。儘管如此，透過開發能夠增強療效並減少副作用的聯合治療、進入醫療基礎設施日益完善的新興市場以及探索他汀類藥物在膽固醇管理之外的新應用（例如抑制炎症和神經保護），治療領域和市場潛力仍有巨大的擴展潛力。
本次調查的主要特點
- 本報告對全球他汀類藥物市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%）。
- 它還強調了各個領域的潛在商機，並解釋了該市場有吸引力的投資提案矩陣。
- 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
- 該報告根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，概述了全球他汀類藥物市場的主要企業。
- 本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
- 全球他汀類藥物市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
- 透過用於分析全球他汀類藥物市場的各種策略矩陣，相關人員將更容易做出決策。
目錄
第 1 章：調查目標與先決條件
- 調查目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告描述
- 市場定義和範圍
- 執行摘要
第3章：市場動態、法規與趨勢分析
- 市場動態
- 驅動程式
- 抑制因素
- 機會
- 影響分析
- 主要進展
- 監管情景
- 產品發布/核准
- PEST分析
- 波特分析
- 併購場景
- 產業趨勢
4. 2020-2032 年全球他汀類藥物市場（依產品類型）
- 學名藥
- 品牌藥
5. 2020-2032 年全球他汀類藥物市場
- Atorvastatin
- 氟伐他汀
- 洛伐他汀
- 普伐他汀
- rosuvastatin
- Simvastatin
- 匹伐他汀
6. 全球他汀類藥物市場（依適應症分類），2020-2032 年
- 預防心肌梗塞
- 中風預防
- 預防第2型糖尿病相關的心肌梗塞和中風
- 降低冠狀動脈疾病的風險
- 原發性高血脂症的治療
- 混合型血脂異常的治療
- 高三酸甘油脂血症和原發性異常BETA脂蛋白血症
- 純合子遺傳性高膽固醇症（HoFH）的治療
- 雜合子遺傳性高膽固醇症（HeFH）（兒童）的治療
7. 2020-2032 年全球他汀類藥物市場（依他汀類藥物類型）
- 天然他汀類藥物
- 合成他汀類藥物
8. 2020-2032 年全球他汀類藥物市場（以劑型分類）
- 藥片
- 膠囊
9. 全球他汀類藥物市場（依實力分類），2020-2032 年
- 10mg
- 20mg
- 40mg
- 80mg
10. 全球他汀類藥物市場依銷售管道，2020-2032
- 處方
- OTC
第 11 章。 2020-2032 年按年齡層分類的全球他汀類藥物市場
- 孩子們
- 成人
- 老年人
第 12 章。 2020-2032 年全球他汀類藥物市場（依性別）
- 男性
- 女士
13. 2020-2032 年全球他汀類藥物市場（依通路）
- 醫院藥房
- 零售藥局
- 網路藥局
第 14 章。 2020-2032 年按地區分列的全球他汀類藥物市場
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太地區
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東地區
- 非洲
- 南非
- 北非
- 中部非洲
第15章競爭格局
- Pfizer Inc.
- AstraZeneca
- Merck & Co.
- Novartis AG
- Medicure Inc.
- Teva Pharmaceutical
- Mylan NV
- Sun Pharmaceutical
- Aurobindo Pharma
- Reddy's Laboratories
- Kowa Pharmaceuticals
- Other Prominent Players
第 16 章分析師建議
- 機會
- 分析師觀點
- Coherent Opportunity Map
第17章參考文獻與調查方法
- 參考
- 調查方法
- 關於出版商
Statins Market is estimated to be valued at USD 17.25 Bn in 2025 and is expected to reach USD 24.96 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.42% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 17.25 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 5.42% | 2032 Value Projection: | USD 24.96 Bn |
The global statins market represents one of the most significant pharmaceutical segments in cardiovascular therapeutics, encompassing cholesterol-lowering medications that have revolutionized the treatment and prevention of heart disease worldwide. Statins, scientifically known as HMG-CoA reductase inhibitors, function by blocking the enzyme responsible for cholesterol synthesis in the liver, effectively reducing low-density lipoprotein (LDL) cholesterol levels and minimizing cardiovascular risk factors. This market has experienced substantial growth driven by the increasing prevalence of hypercholesterolemia, rising awareness of cardiovascular diseases, and expanding geriatric population globally.
The market encompasses various statin formulations including atorvastatin, simvastatin, rosuvastatin, pravastatin, and lovastatin, available in multiple dosage forms and strengths to cater to diverse patient needs. With cardiovascular diseases remaining the leading cause of mortality worldwide, statins have become cornerstone medications in both primary and secondary prevention strategies, supported by extensive clinical evidence demonstrating their efficacy in reducing major adverse cardiovascular events. The market landscape is characterized by the presence of both branded and generic formulations, with patent expirations having significantly impacted pricing dynamics while simultaneously improving accessibility for patients across different economic segments globally.
Market Dynamics
The global statins market is propelled by several compelling drivers, with the escalating prevalence of cardiovascular diseases and hypercholesterolemia serving as primary growth catalysts, particularly as sedentary lifestyles, unhealthy dietary patterns, and obesity rates continue to rise across developed and developing nations. The expanding geriatric population, who are inherently at higher risk for cardiovascular complications, creates sustained demand for cholesterol-lowering therapies, while increasing healthcare expenditure and improved insurance coverage enhance market accessibility. Growing awareness about preventive healthcare measures and routine cholesterol screening programs have led to earlier diagnosis and treatment initiation, further expanding the patient pool requiring statin therapy.
However, the market faces significant restraints including the widespread availability of generic alternatives following patent expirations of major branded statins, which has intensified price competition and compressed profit margins for pharmaceutical companies. Safety concerns related to statin-associated adverse effects such as muscle-related symptoms, liver enzyme elevations, and potential diabetes risk have created hesitancy among some physicians and patients, impacting prescription patterns. Additionally, the emergence of alternative cholesterol-lowering therapies, including PCSK9 inhibitors and newer lipid-modifying agents, poses competitive challenges to traditional statin therapy. Regulatory complexities and stringent approval processes for new formulations or indications create barriers to market entry and innovation. Nevertheless, substantial opportunities exist through the development of combination therapies that enhance efficacy while potentially reducing side effects, expansion into emerging markets with growing healthcare infrastructure, and the exploration of novel statin applications beyond cholesterol management, including potential benefits in inflammation reduction and neuroprotection, which could significantly broaden the therapeutic scope and market potential.
Key Features of the Study
- This report provides in-depth analysis of the global statins market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global statins market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Pfizer Inc, AstraZeneca, Merck & Co, Novartis AG, Medicure Inc., Teva Pharmaceutical, Mylan NV, Sun Pharmaceutical, Aurobindo Pharma, Dr. Reddy's Laboratories, Kowa Pharmaceuticals, and other prominent players.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global statins market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global statins market.
Market Segmentation
- Product Type Insights (Revenue, USD Bn, 2020 - 2032)
- Generic Drugs
- Branded Drugs
- Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Atorvastatin
- Fluvastatin
- Lovastatin
- Pravastatin
- Rosuvastatin
- Simvastatin
- Pitavastatin
- Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Prevention of Myocardial Infarction
- Stroke Prevention
- Type 2 Diabetes-related MI and Stroke Prevention
- Coronary Heart Disease Risk Reduction
- Primary Hyperlipidemia Treatment
- Mixed Dyslipidemia Treatment
- Hypertriglyceridemia and Primary Dysbetalipoproteinemia
- Homozygous Familial Hypercholesterolemia (HoFH) Treatment
- Heterozygous Familial Hypercholesterolemia (HeFH) Treatment (Pediatric)
- Type Of Statin Insights (Revenue, USD Bn, 2020 - 2032)
- Natural Statins
- Synthetic Statins
- Formulation Insights (Revenue, USD Bn, 2020 - 2032)
- Tablets
- Capsules
- Strength Insights (Revenue, USD Bn, 2020 - 2032)
- 10 mg
- 20 mg
- 40 mg
- 80 mg
- Sales Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Prescription
- Over-the-Counter
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Pediatric
- Adult
- Geriatric
- Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- AstraZeneca
- Merck & Co
- Novartis AG
- Medicure Inc.
- Teva Pharmaceutical
- Mylan NV
- Sun Pharmaceutical
- Aurobindo Pharma
- Reddy's Laboratories
- Kowa Pharmaceuticals
- Other Prominent Players
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Statins Market, By Product Type
- Global Statins Market, By Drug Class
- Global Statins Market, By Indication
- Global Statins Market, By Type of Statin
- Global Statins Market, By Formulation
- Global Statins Market, By Strength
- Global Statins Market, By Sales Channel
- Global Statins Market, By Age Group
- Global Statins Market, By Gender
- Global Statins Market, By Distribution Channel
- Global Statins Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Statins Market, By Product Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Generic Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Branded Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Statins Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Atorvastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Fluvastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Lovastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pravastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Rosuvastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Simvastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pitavastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Statins Market, By Indication, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Prevention of Myocardial Infarction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Stroke Prevention
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Type 2 Diabetes-related MI and Stroke Prevention
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Coronary Heart Disease Risk Reduction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Primary Hyperlipidemia Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Mixed Dyslipidemia Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hypertriglyceridemia and Primary Dysbetalipoproteinemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Homozygous Familial Hypercholesterolemia (HoFH) Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Heterozygous Familial Hypercholesterolemia (HeFH) Treatment (Pediatric)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Statins Market, By Type of Statin, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Natural Statins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Synthetic Statins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Statins Market, By Formulation, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Statins Market, By Strength, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- 10 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 20 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 40 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 80 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Statins Market, By Sales Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Prescription
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Over-the-Counter
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Statins Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
12. Global Statins Market, By Gender, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
13. Global Statins Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
14. Global Statins Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
15. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Medicure Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan NV
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aurobindo Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Kowa Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Other Prominent Players
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
16. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
17. References and Research Methodology
- References
- Research Methodology
- About us
